Literature DB >> 17373918

Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn's disease.

X Roblin1, J M Phelip, M Genevois, V Ducros, B Bonaz.   

Abstract

BACKGROUND: A high prevalence of osteoporosis is observed in Crohn's disease. Recent data have shown that homocysteinaemia is an important risk factor in low-bone mineralization and fracture. AIM: To look for an association between homocysteinaemia and low-bone mineralization in Crohn's disease patients. PATIENTS AND METHODS: Ninety-two consecutive patients (sex ratio M/F 0.87; mean age: 36.6 +/- 13.2 years) were recruited between 2003 and 2005. Bone densitometry was performed on inclusion. The following parameters were analysed: age, sex, Crohn's Disease Activity Index, duration and extent of Crohn's disease, smoking status, corticosteroid treatment, immunosuppressive drugs, plasma homocysteine, folate and vitamin B12 concentration.
RESULTS: The prevalence of a high homocysteine level (>15 micromol/L) was 60%. Osteoporosis and low-bone mineralization observed in 26 (28%), and 60 (65%) patients, respectively. On a multivariate analysis, associated factors for osteoporosis and low-bone mineralization were respectively: hyperhomocysteinaemia (OR: 61.4; CI: 95: 23-250; P < 0.001), and ileal Crohn's disease [OR: 13.8; CI: 95: 2.5-150; P = 0.036] for osteoporosis and hyperhomocysteinaemia [OR: 63.7; CI: 95: 8.5-250; P < 0.001] and disease duration of at least 5 years [OR: 11.4; CI: 95: 1.31-99; P = 0.039] for low-bone mineralization. Results were similar whichever site osteoporosis was detected.
CONCLUSION: Hyperhomocysteinaemia was observed in 60% of our Crohn's disease patients and was strongly associated with low-bone mineralization and osteoporosis (OR: 61.4).

Entities:  

Mesh:

Year:  2007        PMID: 17373918     DOI: 10.1111/j.1365-2036.2007.03260.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Proton pump inhibitors and fracture risk: true effect or residual confounding?

Authors:  Michael Bodmer; Christian Meier; Marius E Kraenzlin; Christoph R Meier
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

Review 2.  The role of homocysteine in bone remodeling.

Authors:  Thomas P Vacek; Anuradha Kalani; Michael J Voor; Suresh C Tyagi; Neetu Tyagi
Journal:  Clin Chem Lab Med       Date:  2013-03-01       Impact factor: 3.694

3.  Low bone mineral density in Greek patients with inflammatory bowel disease: prevalence and risk factors.

Authors:  Ioannis E Koutroubakis; Christos Zavos; John Damilakis; Georgios Z Papadakis; John Neratzoulakis; Nikolaos Karkavitsas; Elias A Kouroumalis
Journal:  Ann Gastroenterol       Date:  2011

Review 4.  Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases.

Authors:  Alicja Ewa Ratajczak; Anna Maria Rychter; Agnieszka Zawada; Agnieszka Dobrowolska; Iwona Krela-Kaźmierczak
Journal:  Nutrients       Date:  2020-06-06       Impact factor: 5.717

Review 5.  The Role of Methyl Donors of the Methionine Cycle in Gastrointestinal Infection and Inflammation.

Authors:  Joseph A Vaccaro; Saleh A Naser
Journal:  Healthcare (Basel)       Date:  2021-12-29

Review 6.  Osteoporosis Complications in Crohn's Disease Patients: Factors, Pathogenesis, and Treatment Outlines.

Authors:  Yaqot N Baban; Christopher M Edicheria; Joseph Joseph; Parneet Kaur; Jihan A Mostafa
Journal:  Cureus       Date:  2021-12-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.